EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Spencer I Danto, Nikolaos Tsamandouras, Padmalatha Reddy, Steven Gilbert, Jessica Mancuso, Karen Page, Elena Peeva, Michael S Vincent, Jean S Beebe

The Journal of Clinical Pharmacology · 2024-05 · 64 (5) · 529-543

DOI: 10.1002/jcph.2360 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 30.10.2023. Verfasst von Spencer I Danto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Nasal Polyps, Rhinosinusitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PF‐06817024 is a high affinity, humanized antibody that binds interleukin‐33, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized, placebo‐controlled study was conducted in 3 parts to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics of escalating single and limited repeat PF‐06817024 doses in healthy participants (Part 1), a single dose of PF‐06817024 in participants with chronic rhinosinusitis with nasal polyps (Part 2), and repeat doses of PF‐06817024 in participants with moderate to severe atopic dermatitis (atoptic dermatitis; Part 3). PF‐06817024 was generally well tolerated in all participant populations. Most participants experienced a treatment‐emergent adverse event (healthy participants, 78.4% and 100%; participants with chronic rhinosinusitis with nasal polyps, 90.9% and 88.9%; and participants with atoptic dermatitis, 60.0% and 62.5% in the PF‐06817024 and placebo groups, respectively). No substantial deviations from dose proportionality were observed for single intravenous doses of 10‐1000 mg, indicating linear PK in healthy participants. Mean terminal half‐life ranged from 83 to 94 days after single intravenous administration in healthy participants and was similar to that observed after administration in the studied patient populations. Incidences of antidrug antibodies in the studied populations were 10.8%, 9.1%, and 5.0% for healthy participants, participants with chronic rhinosinusitis with nasal polyps, and participants with atoptic dermatitis, respectively. In addition, dose‐dependent increases were observed in total serum interleukin‐33 levels of treated participants, indicating target engagement. Overall, the PK and safety profile of PF‐06817024 supports further investigation of the drug as a potential treatment for allergic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicNasal PolypsRhinosinusitisAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAntibodies, Monoclonal, HumanizedChronic DiseaseDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersInterleukin-33

Stichwörter der Autor:innen

Phase 1anti‐IL‐33 antibodyatopic dermatitischronic rhinosinusitis with nasal polypshealthy participantssafety

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-33

Autor:innen und Institutionen

  • Pfizer Inc, Cambridge, MA, USA.

Zitieren

APA

Danto, S. I., Tsamandouras, N., Reddy, P., Gilbert, S., Mancuso, J., Page, K., Peeva, E., Vincent, M. S., & Beebe, J. S. (2024). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study. The Journal of Clinical Pharmacology, 64(5), 529-543. https://doi.org/10.1002/jcph.2360

Vancouver

Danto SI, Tsamandouras N, Reddy P, Gilbert S, Mancuso J, Page K, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 2024;64(5):529-543. doi:10.1002/jcph.2360

BibTeX
@article{Danto2024,
  author = {Danto, Spencer I and Tsamandouras, Nikolaos and Reddy, Padmalatha and Gilbert, Steven and Mancuso, Jessica and Page, Karen and Peeva, Elena and Vincent, Michael S and Beebe, Jean S},
  title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  volume = {64},
  number = {5},
  pages = {529--543},
  doi = {10.1002/jcph.2360}
}
Kostenlos starten →